Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Vaccines (Basel) ; 12(5)2024 Apr 24.
Article in English | MEDLINE | ID: mdl-38793702

ABSTRACT

COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has significantly impacted public health and the economy worldwide. Most of the currently licensed COVID-19 vaccines act by inhibiting the receptor-binding function of the SARS-CoV-2 spike protein. The constant emergence of SARS-CoV-2 variants resulting from mutations in the receptor-binding domain (RBD) leads to vaccine immune evasion and underscores the importance of broadly acting COVID-19 vaccines. Inactivated whole virus vaccines can elicit broader immune responses to multiple epitopes of several antigens and help overcome such immune evasions. We prepared a psoralen-inactivated SARS-CoV-2 vaccine (SARS-CoV-2 PsIV) and evaluated its immunogenicity and efficacy in nonhuman primates (NHPs) when administered with the Advax-CpG adjuvant. We also evaluated the SARS-CoV-2 PsIV as a booster shot in animals vaccinated with a DNA vaccine that can express the full-length spike protein. The Advax-CpG-adjuvanted SARS-CoV-2 PsIV elicited a dose-dependent neutralizing antibody response in the NHPs, as measured using a serum microneutralization assay against the SARS-CoV-2 Washington strain and the Delta variant. The animals vaccinated with the DNA vaccine followed by a boosting dose of the SARS-CoV-2 PsIV exhibited the highest neutralizing antibody responses and were able to quickly clear infection after an intranasal challenge with the SARS-CoV-2 Delta variant. Overall, the data show that the Advax-CpG-adjuvanted SARS-CoV-2 PsIV, either by itself or as a booster shot following nucleic acid (NA) vaccines, has the potential to protect against emerging variants.

2.
Microorganisms ; 10(5)2022 May 16.
Article in English | MEDLINE | ID: mdl-35630476

ABSTRACT

Dengue fever, caused by any of four dengue viruses (DENV1-4), is a major global burden. Currently, there is no effective vaccine that prevents infection in dengue naïve populations. We tested the ability of two novel adjuvants (Advax-PEI and Advax-2), using aluminum hydroxide (alum) as control, to enhance the immunogenicity of formalin- or psoralen-inactivated (PIV or PsIV) DENV2 vaccines in mice. Mice were vaccinated on days 0 and 30, and serum samples were collected on days 30, 60, 90, and 101. Neutralizing antibodies were determined by microneutralization (MN) assays, and the geometric mean 50% MN (MN50) titers were calculated. For the PIV groups, after one dose MN50 titers were higher in the novel adjuvant groups compared to the alum control, while MN50 titers were comparable between the adjuvant groups after the second dose. For the PsIV groups, both novel adjuvants induced higher MN50 titers than the alum control after the second dose. Spleen cells were collected on days 45 and 101 for enzyme-linked immunospot (ELISPOT) for IFNγ and IL4. Both PIV and PsIV groups elicited different degrees of IFNγ and IL4 responses. Overall, Advax-2 gave the best responses just ahead of Advax-PEI. Given Advax-2's extensive human experience in other vaccine applications, it will be pursued for further development.

3.
Vaccine ; 40(6): 961-966, 2022 02 07.
Article in English | MEDLINE | ID: mdl-35031146

ABSTRACT

BACKGROUND: During routine mass live-attenuated influenza vaccination (LAIV) for military personnel, emergent deployment for Ebola humanitarian assistance (OUA) required mass yellow fever vaccination (YF17D), often < 4-weeks recommended timing post-LAIV-triggering concerns for immune interference. We compared YF17D seroconversion rates in personnel who received YF17D as recommended (vaccinated by guidelines [VBG]) to those who received the vaccine outside the recommended timing following LAIV (not vaccinated by guidelines [NVBG]). METHODS: OUA deploying personnel who received LAIV simultaneously or before YF17D and had pre- and post-vaccination archived serum were included. VBG was defined as YF17D given concurrently or ≥ 30 days post-LAIV and NVBG as YF17D given 1-29 days post-LAIV. YF17D seroresponse was determined by screening ELISA confirmed with plaque reduction neutralization testing (PRNT) on positive ELISA samples. Exclusion criteria were prior YF17D and pre-vaccination YF17D positive PRNT. RESULTS: Of the 660 personnel included, 507 were VBG and 153 were NVBG. Median age was 25 years for both groups. Men accounted for 84% of those VBG and 79% NVBG (p = 0.194). Seroconversion rates were 97.8% for VBG and 95.4% for NVBG (p = 0.15). Multivariate logistic regression revealed that YF17D on days 7-21 post-LAIV (adjusted odds ratio [aOR] 0.304, p = 0.017; confidence interval [CI] 0.114-0.810) and female sex (aOR 0.330, p = 0.026; CI 0.124-0.879) were associated with decreased seroresponse. CONCLUSIONS: In this healthy, young adult military population, there was high seroconversion following YF17D when administered simultaneously and at various time points after LAIV. Slight decreases in seroresponse were seen in women and those receiving YF17D 7-21 days following LAIV.


Subject(s)
Influenza Vaccines , Influenza, Human , Yellow Fever , Adult , Female , Humans , Male , Vaccination , Vaccines, Attenuated , Young Adult
4.
Pathogens ; 10(5)2021 May 19.
Article in English | MEDLINE | ID: mdl-34069575

ABSTRACT

The development of a safe and effective vaccine to protect against COVID-19 is a global priority due to the current high SARS-CoV-2 infection rate. Currently, there are over 160 SARS-CoV-2 vaccine candidates at the clinical or pre-clinical stages of development. Of these, there are only three whole-virus vaccine candidates produced using ß-propiolactone or formalin inactivation. Here, we prepared a whole-virus SARS-CoV-2 vaccine (SARS-CoV-2 PsIV) using a novel psoralen inactivation method and evaluated its immunogenicity in mice using two different adjuvants, alum and Advax-2. We compared the immunogenicity of SARS-CoV-2 PsIV against SARS-CoV-2 DNA vaccines expressing either full-length or truncated spike proteins. We also compared the psoralen-inactivated vaccine against a DNA prime, psoralen-inactivated vaccine boost regimen. After two doses, the psoralen-inactivated vaccine, when administered with alum or Advax-2 adjuvants, generated a dose-dependent neutralizing antibody responses in mice. Overall, the pattern of cytokine ELISPOT responses to antigen-stimulation observed in this study indicates that SARS-CoV-2 PsIV with the alum adjuvant promotes a Th2-type response, while SARS-CoV-2 PsIV with the Advax-2 adjuvant promotes a Th1-type response.

5.
Vaccine ; 38(17): 3313-3320, 2020 04 09.
Article in English | MEDLINE | ID: mdl-32184032

ABSTRACT

Dengue fever, caused by dengue viruses (DENV 1-4) is a leading cause of illness and death in the tropics and subtropics. Therefore, an effective vaccine is urgently needed. Currently, the only available licensed dengue vaccine is a chimeric live attenuated vaccine that shows varying efficacy depending on serotype, age and baseline DENV serostatus. Accordingly, a dengue vaccine that is effective in seronegative adults, children of all ages and in immunocompromised individuals is still needed. We are currently researching the use of psoralen to develop an inactivated tetravalent dengue vaccine. Unlike traditional formalin inactivation, psoralen inactivates pathogens at the nucleic acid level, potentially preserving envelope protein epitopes important for protective anti-dengue immune responses. We prepared highly purified monovalent vaccine lots of formalin- and psoralen-inactivated DENV 1-4, using Capto DeVirS and Capto Core 700 resin based column chromatography. Tetravalent psoralen-inactivated vaccines (PsIV) and formalin-inactivated vaccines (FIV) were prepared by combining the four monovalent vaccines. Mice were immunized with either a low or high dose of PsIV or FIV to evaluate the immunogenicity of monovalent as well as tetravalent formulations of each inactivation method. In general, the monovalent and tetravalent PsIVs elicited equivalent or higher titers of neutralizing antibodies to DENV than the FIV dengue vaccines and this response was dose dependent. The immunogenicity of tetravalent dengue PsIVs and FIVs were also evaluated in nonhuman primates (NHPs). Consistent with what was observed in mice, significantly higher neutralizing antibody titers for each dengue serotype were observed in the NHPs vaccinated with the tetravalent dengue PsIV compared to those vaccinated with the tetravalent dengue FIV, indicative of the importance of envelope protein epitope preservation during psoralen inactivation of DENV.


Subject(s)
Dengue Vaccines/immunology , Dengue , Ficusin , Formaldehyde , Immunogenicity, Vaccine , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Dengue/prevention & control , Mice , Primates , Vaccines, Inactivated/immunology
6.
J Immunol Methods ; 441: 24-30, 2017 02.
Article in English | MEDLINE | ID: mdl-27856192

ABSTRACT

The study assessed antibody-dependent NK cell degranulation, a biomarker relevant to antibody-dependent cell cytotoxicity (ADCC), to analyze dengue immune sera. We first determined binding intensity of patient sera to the surface of DENV-infected cells and examined the types of antigens expressed on infected cells. Antigens from pre-membrane (PreM) and envelope (E), but not from NS proteins were detected on the surface of infected cells. After adding NK cells to infected target cells previously treated with patient sera, rapid NK cell degranulation was observed. Non-neutralizing patient sera generated comparable NK cell degranulation as that of neutralizing sera, suggesting ADCC may be a protective mechanism apart from Ab neutralization. The level of NK cell degranulation varied dramatically among human individuals and was associated with the level of CD16 expression on NK cells, informing on the complexity of ADCC among human population.


Subject(s)
Antibodies, Neutralizing/immunology , Antibody-Dependent Cell Cytotoxicity , Cell Degranulation , Dengue Virus/immunology , Dengue/immunology , Killer Cells, Natural/immunology , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Antibodies, Viral/immunology , GPI-Linked Proteins/genetics , GPI-Linked Proteins/immunology , Humans , Receptors, IgG/genetics , Receptors, IgG/immunology
7.
Virology ; 421(2): 245-52, 2011 Dec 20.
Article in English | MEDLINE | ID: mdl-22033262

ABSTRACT

Human monocytes are susceptible to dengue virus (DV) infection through an FcR-dependent pathway known as antibody-dependent enhancement (ADE). In this study, infection enhancement was observed when purified monocytes were infected with DV serotypes in the presence of serially diluted immune serum antibodies. Analyzing binding of the DV-antibody immune complexes to monocytes by quantifying the amount of viruses attached to monocytes, we found that binding did not correlate with the input amount of antibodies; rather, it peaked at suboptimal antibody concentrations, correlating with the observed infection enhancement. These results suggested that immune complexes are involved in hindering DV from binding to FcR-bearing cells; when such a protective feature is weakened, enhancement of viral attachment and ADE are observed. Further, increased cytokine production (TNF-alpha and IFN-alpha), and costimulatory marker expression (CD86 and CD40), were found to be associated with infection enhancement, suggesting a pathological role of ADE-affected monocytes in dengue hemorrhagic diseases.


Subject(s)
Antibodies, Viral/immunology , Antibody-Dependent Enhancement , Dengue Virus/immunology , Leukocytes, Mononuclear/immunology , Animals , Antibodies, Neutralizing/immunology , Antibodies, Neutralizing/metabolism , Antibodies, Viral/metabolism , Antibody Affinity , B7-2 Antigen/biosynthesis , CD40 Antigens/biosynthesis , Chlorocebus aethiops , Dengue Virus/metabolism , Dengue Virus/physiology , Humans , Interferon-alpha/biosynthesis , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/virology , Severe Dengue/immunology , Severe Dengue/virology , Tumor Necrosis Factor-alpha/biosynthesis , Vero Cells , Virus Replication
8.
J Virol Methods ; 173(2): 175-81, 2011 May.
Article in English | MEDLINE | ID: mdl-21315764

ABSTRACT

Dengue envelope (E) protein is a dominant immune inducer and E protein-based vaccines elicited partial to complete protection in non-human primates. To study the immunogenicity of these vaccines in humans, an enzyme linked immunospot (ELISPOT) assay for measuring interferon gamma (IFN-γ) production was developed. Cells from two subject groups, based on dengue-exposure, were selected for assay development. The unique feature of the IFN-γ ELISPOT assay is the utilization of dendritic cells pulsed with E proteins as antigen presenting cells. IFN-γ production, ranging from 53-513 spot forming units per million peripheral blood mononuclear cells (PBMCs), was observed in dengue-exposed subjects as compared to 0-45 IFN-γ spot forming units in dengue-unexposed subjects. Further, both CD4(+) and CD8(+) T cells, and cells bearing CD45RO memory marker, were the major sources of IFN-γ production. The assay allowed quantification of E-specific IFN-γ-secreting memory T cells in subjects 9 years after exposure to a live-attenuated virus vaccine and live-virus challenge. Results suggested that the dendritic cell-based IFN-γ assay is a useful tool for assessing immunological memory for clinical research.


Subject(s)
Blood/immunology , Clinical Laboratory Techniques/methods , Dendritic Cells/immunology , Dengue Vaccines/immunology , Immunologic Memory , T-Lymphocyte Subsets/immunology , Viral Envelope Proteins/immunology , CD4-Positive T-Lymphocytes/chemistry , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/chemistry , CD8-Positive T-Lymphocytes/immunology , Cells, Cultured , Enzyme-Linked Immunospot Assay/methods , Humans , Interferon-gamma/metabolism , Leukocyte Common Antigens/analysis
9.
Virology ; 383(2): 207-15, 2009 Jan 20.
Article in English | MEDLINE | ID: mdl-19013627

ABSTRACT

Myeloid and plasmacytoid dendritic cells (mDC and pDC) are naturally distinctive subsets. We exposed both subsets to dengue virus (DV) in vitro and investigated their functional characteristics. High levels of DV replication in mDC were found to correlate with DC-SIGN expression. Production of inflammatory cytokines by mDC increased gradually after DV-infection, which was dependent on DV replication. Co-stimulatory markers were upregulated on mDC upon DV-infection. On the contrary, lower levels of DV-replication were observed in pDC, but the cytokine production in pDC was quicker and stronger. This cytokine response was not dependent on viral replication, but dependent on cell endosomal activity and TLR7, and could be also induced by purified DV genome RNA. These results clearly suggested functional differences between mDC and pDC in response to DV infection. Additionally, the TLR7-mediated recognition of DV RNA may be involved in pDC functional activation.


Subject(s)
Dendritic Cells/immunology , Dendritic Cells/virology , Dengue Virus/immunology , Dengue Virus/physiology , Virus Replication , Cell Adhesion Molecules/biosynthesis , Cytokines/biosynthesis , Endosomes/metabolism , Humans , Lectins, C-Type/biosynthesis , RNA, Viral/immunology , Receptors, Cell Surface/biosynthesis , Toll-Like Receptor 7/metabolism
10.
J Gen Physiol ; 132(5): 563-73, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18852304

ABSTRACT

Activation of the purinergic P2X(7) receptor leads to the rapid opening of an integral ion channel that is permeable to small cations. This is followed by a gradual increase in permeability to fluorescent dyes by integrating the actions of the pannexin-1 channel. Here, we show that during the prolonged agonist application a rapid current that peaked within 200 ms was accompanied with a slower current that required tens of seconds to reach its peak. The secondary rise in current was observed under different ionic conditions and temporally coincided with the development of conductivity to larger organic cations. The biphasic response was also observed in cells with blocked pannexin channels and in cells not expressing these channels endogenously. The biphasic current was preserved in N-terminal T15A, T15S, and T15V mutants that have low or no permeability to organic cations, reflecting enhanced permeability to inorganic cations. In contrast, the T15E, T15K, and T15W mutants, and the Delta18 mutant with deleted P2X(7) receptor-specific 18-amino acid C-terminal segment, were instantaneously permeable to organic cations and generated high amplitude monophasic currents. These results indicate that the P2X(7) receptor channel dilates under physiological ion conditions, leading to generation of biphasic current, and that this process is controlled by residues near the intracellular side of the channel pore.


Subject(s)
Ion Channel Gating/drug effects , Ion Channel Gating/physiology , Protein Interaction Domains and Motifs/physiology , Receptors, Purinergic P2/physiology , Amino Acid Substitution , Animals , Cations/pharmacology , Cell Line, Transformed , Cell Line, Tumor , Cell Membrane Permeability , Connexins/drug effects , Connexins/metabolism , Electric Conductivity , Humans , Ion Transport/drug effects , Ion Transport/physiology , Kinetics , Mice , Mutagenesis, Site-Directed , Nerve Tissue Proteins/drug effects , Nerve Tissue Proteins/metabolism , Particle Size , Protein Interaction Domains and Motifs/drug effects , Purinergic P2 Receptor Agonists , Rats , Receptors, Purinergic P2X7 , Structure-Activity Relationship , Thermodynamics
11.
J Neurochem ; 102(4): 1139-50, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17663752

ABSTRACT

The localization of ATP binding site(s) at P2X receptors and the molecular rearrangements associated with opening and closing of channels are still not well understood. At P2X(4) receptor, substitution of the K67, F185, K190, F230, R278, D280, R295, and K313 ectodomain residues with alanine generated low or non-responsive mutants, whereas the F294A mutant was functional. The loss of receptor function was also observed in K67R, R295K, and K313R mutants, but not in F185W, K190R, F230W, R278K, and D280E mutants. To examine whether the loss of function reflects decreased sensitivity of mutants for ATP, we treated cells with ivermectin, an antiparasitic agent that enhances responsiveness of P2X(4)R. In the presence of ivermectin, all low or non-responsive mutants responded to ATP in a dose-dependent manner, with the EC(50) values for ATP of about 1, 2, 4, 20, 60, 125, 270, 420, 1000 and 2300 micromol/L at D280A, R278A, F185A, K190A, R295K, K313R, R295A, K313A, K67A and K67R mutants, respectively. These results indicate that lysines 67 and 313 and arginine 295 play a critical role in forming the proper three-dimensional structure of P2X(4)R for agonist binding and/or channel gating.


Subject(s)
Amino Acids, Aromatic/physiology , Receptors, Purinergic P2/chemistry , Receptors, Purinergic P2/physiology , Adenosine Triphosphate/pharmacology , Animals , Binding Sites/drug effects , Cell Line, Transformed , Dose-Response Relationship, Drug , Gonadotropin-Releasing Hormone/metabolism , Humans , Hypothalamus/cytology , Ivermectin/pharmacology , Membrane Potentials/drug effects , Membrane Potentials/radiation effects , Mice , Mutagenesis, Site-Directed/methods , Neurons/metabolism , Patch-Clamp Techniques , Protein Binding/drug effects , Receptors, Purinergic P2X4 , Structure-Activity Relationship , Transfection
12.
Biochem Biophys Res Commun ; 349(2): 619-25, 2006 Oct 20.
Article in English | MEDLINE | ID: mdl-16949036

ABSTRACT

Ivermectin (IVM) applied extracellularly increases the sensitivity of P2X4 receptor (P2X4R) to ATP, enhances the maximum current amplitudes, and greatly prolongs the deactivation kinetics. In this manuscript, we focused on identification of receptor-specific residues responsible for IVM effects on channel gating using the wild-type rat homomeric P2X4R, several chimeric P2X2/P2X4 receptors, and single-point P2X4R-specific mutants in the ectodomain and two transmembrane domains. Experiments with chimeric receptors revealed that the Val49-Val61 but not the Val64-Tyr315 ectodomain sequence is important for the effects of IVM on channel deactivation. Receptor-specific mutations placed in the Gly29-Val61 and Asp338-Leu358 regions showed the importance of Trp50, Val60, and Val357 residues in IVM regulation of the rate of channel deactivation, but not on the maximum current amplitude. These results suggest that the transmembrane domains and the nearby ectodomain region contribute to the effects of IVM on channel deactivation.


Subject(s)
Ivermectin/chemistry , Receptors, Purinergic P2/chemistry , Adenosine Triphosphate/chemistry , Amino Acid Sequence , Animals , Antiparasitic Agents/pharmacology , Dose-Response Relationship, Drug , Humans , Ivermectin/pharmacology , Molecular Sequence Data , Rats , Receptors, Purinergic P2X4 , Sequence Homology, Amino Acid , Tryptophan/chemistry , Valine/chemistry
13.
J Biol Chem ; 281(43): 32649-59, 2006 Oct 27.
Article in English | MEDLINE | ID: mdl-16954225

ABSTRACT

To study the roles of the Lys(313)-Ile(333) ectodomain sequence of the rat P2X(4) receptor in ATP binding and transduction of signals to the channel gate, the conserved Lys(313), Tyr(315), Gly(316), Ike(317), Arg(318), Asp(320), Val(323), Lys(329), Phe(330), and Ile(333) residues were mutated. Current recordings were done on lifted cells and ATP was applied using an ultrafast solution-switching system. The rates of wild type channel opening and closing in the presence of ATP, but not the rate of washout-induced closing, were dependent on agonist concentration. All mutants other than I317A were expressed in the plasma membrane at comparable levels. The majority of mutants showed significant changes in the peak amplitude of responses and the EC(50) values for ATP. When stimulated with the supramaximal (1.4 mm) ATP concentration, mutants also differed in the kinetics of their activation, deactivation, and/or desensitization. The results suggest a critical role of the Lys(313) residue in receptor function other than coordination of the phosphate group of ATP and possible contribution of the Tyr(315) residue to the agonist binding module. The pattern of changes of receptor function by mutation of other residues was consistent with the operation of the Gly(316)-Ile(333) sequence as a signal transduction module between the ligand binding domain and the channel gate in the second transmembrane domain.


Subject(s)
Ion Channel Gating , Isoleucine/chemistry , Leucine/chemistry , Purinergic P2 Receptor Agonists , Receptors, Purinergic P2/chemistry , Signal Transduction , Amino Acid Sequence , Animals , Binding Sites , Cell Line , Conserved Sequence , Humans , Hydrogen Bonding , Models, Molecular , Molecular Sequence Data , Mutation , Protein Structure, Secondary , Protein Structure, Tertiary , Rats , Receptors, Purinergic P2/genetics , Receptors, Purinergic P2/metabolism , Sequence Homology, Amino Acid , Transfection
14.
Mol Pharmacol ; 67(4): 1078-88, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15632318

ABSTRACT

P2 purinergic receptor channel receptors (P2XRs) are a family of ligand-gated cation channels composed of two transmembrane domains, N and C termini located intracellularly, and a large extracellular loop containing the ATP binding domain. To identify regions important for binding and gating, previous experimental work was focused on mutagenesis of conserved ectodomain residues. Here, we used the known sequence and secondary structure similarities between the Lys180-Lys326 ectodomain region of P2X(4) and the class II aminoacyl-tRNA synthetases as a guide to generate a three-dimensional model of the receptor-binding site and to design mutants. The interplay between homology modeling and site-directed mutagenesis suggested that Asp280 residue of P2X(4)R coordinates ATP binding via the magnesium ion, Phe230 residue coordinates the binding of the adenine ring of ATP, and Lys190, His286, and Arg278 residues coordinate the actions of negatively charged alpha-, beta-, and gamma-phosphate groups, respectively. Until the crystal structure of the channel is solved, this model could provide a useful approach for future studies on the identification of ATP binding domain and gating of P2XRs.


Subject(s)
Adenosine Triphosphate/metabolism , Receptors, Purinergic P2/chemistry , Animals , Binding Sites , Cells, Cultured , Guinea Pigs , Humans , Mice , Models, Molecular , Mutagenesis, Site-Directed , Purinergic P2 Receptor Agonists , Rats , Receptors, Purinergic P2/metabolism , Receptors, Purinergic P2X
SELECTION OF CITATIONS
SEARCH DETAIL
...